Cullinan Therapeutics (CGEM) Prepaid Assets (2020 - 2026)
Cullinan Therapeutics (CGEM) posted quarterly Prepaid Assets of $9.5 million for Q1 2026, down 31.72% year-over-year from $13.9 million in Q1 2025, and up 7.47% quarter-over-quarter from $8.9 million in Q4 2025.
Analysis
Cullinan Therapeutics (CGEM) Prepaid Assets (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Prepaid Assets history runs 7 years deep, the most recent figure standing at $9.5 million for Q1 2026.
- In Q1 2026, Prepaid Assets fell 31.72% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $9.5 million (down 31.72% YoY), while the FY2025 annual figure was $8.9 million, down 43.53% from the prior year.
- Prepaid Assets for Q1 2026 stood at $9.5 million, up from $8.9 million in the prior quarter.
- The five-year high for Prepaid Assets was $15.7 million in Q4 2024, with the low at $619000.0 in Q3 2022.
- The 5-year median for Prepaid Assets is $9.6 million (2025), against an average of $9.4 million.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets tumbled 94.77% in 2023, then jumped 2372.37% in 2024.
- Cullinan Therapeutics' Prepaid Assets stood at $7.2 million in 2022, then surged by 82.79% to $13.1 million in 2023, then gained by 19.56% to $15.7 million in 2024, then plunged by 43.53% to $8.9 million in 2025, then grew by 7.47% to $9.5 million in 2026.
- Business Quant data shows CGEM's Prepaid Assets at $9.5 million in Q1 2026, $8.9 million in Q4 2025, and $9.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.44 Mn |
| Mar 31, 2026 | 9.52 Mn |
| Dec 31, 2025 | 8.86 Mn |
| Sep 30, 2025 | 9.64 Mn |
| Jun 30, 2025 | 10.43 Mn |
| Mar 31, 2025 | 13.95 Mn |
| Dec 31, 2024 | 15.69 Mn |
| Sep 30, 2024 | 13.96 Mn |
| Jun 30, 2024 | 15.30 Mn |
| Mar 31, 2024 | 12.71 Mn |
| Dec 31, 2023 | 13.12 Mn |
| Sep 30, 2023 | 10.28 Mn |
| Jun 30, 2023 | 6.44 Mn |
| Mar 31, 2023 | 8.33 Mn |
| Dec 31, 2022 | 7.18 Mn |
| Sep 30, 2022 | 6.12 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 7.46 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 7.79 Mn |